Research programme: chimeric antigen receptor T-cell therapies - bluebird bio/ViroMedAlternative Names: CAR T-cell therapies - bluebird bio/ViroMed
Latest Information Update: 23 Dec 2015
At a glance
- Originator ViroMed Co Ltd
- Developer bluebird bio
- Class CAR-T cell therapies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours